Sulfopin, a selective covalent inhibitor of Pin1, blocks Myc-driven tumor initiation and growth in vivo
Dubiella, C.; Pinch, B. J.; Zaidman, D.; Manz, T. D.; Poon, E.; He, S.; Resnick, E.; Langer, E. M.; Daniel, C. J.; Seo, H.-S.; Chen, Y.; Ficarro, S. B.; Jamin, Y.; Lian, X.; Kibe, S.; Kozono, S.; Koikawa, K.; Doctor, Z. M.; Nabet, B.; Browne, C. M.; Yang, A.; Stoler-Barak, L.; Shah, R. B.; Vangos, N. E.; Geffken, E. A.; Oren, R.; Sidi, S.; Shulman, Z.; Wang, C.; Marto, J. A.; Dhe-Paganon, S.; Look, T.; Zhou, X. Z.; Lu, K. P.; Sears, R. C.; Chesler, L.; Gray, N. S.; London, N.
Show abstract
The peptidyl-prolyl cis-trans isomerase, Pin1, acts as a unified signaling hub that is exploited in cancer to activate oncogenes and inactivate tumor suppressors, in particular through up-regulation of c-Myc target genes. However, despite considerable efforts, Pin1 has remained an elusive drug target. Here, we screened an electrophilic fragment library to discover covalent inhibitors targeting Pin1s active site nucleophile - Cys113, leading to the development of Sulfopin, a double-digit nanomolar Pin1 inhibitor. Sulfopin is highly selective for Pin1, as validated by two independent chemoproteomics methods, achieves potent cellular and in vivo target engagement, and phenocopies genetic knockout of Pin1. Although Pin1 inhibition had a modest effect on viability in cancer cell cultures, Sulfopin induced downregulation of c-Myc target genes and reduced tumor initiation and tumor progression in murine and zebrafish models of MYCN-driven neuroblastoma. Our results suggest that Sulfopin is a suitable chemical probe for assessing Pin1-dependent pharmacology in cells and in vivo. Moreover, these studies indicate that Pin1 should be further investigated as a potential cancer target.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Coupling cellular drug-target engagement to downstream pharmacology with CeTEAM 97%
- Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function 97%
- Structure-guided bifunctional molecules hit a DEUBAD-lacking hRpn13 species upregulated in multiple myeloma 97%
Similar papers in this journal
- Identification of nonsense-mediated decay inhibitors that alter the tumor immune landscape 96%
- SDR enzymes oxidize specific lipidic alkynylcarbinols into cytotoxic protein-reactive species 96%
- Affinity-guided labeling reveals P2X7 nanoscale membrane redistribution during BV2 microglial activation 95%
Similar papers in this journal
- Peptide-mediated inhibition of the transcriptional regulator Elongin BC induces apoptosis in cancer cells 96%
- A direct high-throughput protein quantification strategy facilitates discovery and characterization of a celastrol-derived BRD4 degrader 96%
- Structural basis for the binding selectivity of human CDY chromodomains 95%
Similar papers in this journal
- CRISPR metabolic screen identifies ATM and KEAP1 as targetable genetic vulnerabilities in solid tumors. 95%
- Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer 95%
- Structural basis for stereospecific inhibition of ASCT2 from rational design 95%
Similar papers in this journal
- In-cell proximity target validation methods for heterobifunctional molecules with CRBN- or VHL-binder using AirID 95%
- Single Cell Profiling Distinguishes Leukemia-Selective Chemotypes 95%
- Partial inhibition of mitochondrial complex I attenuates neurodegeneration and restores energy homeostasis and synaptic function in a symptomatic Alzheimers mouse model 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.